Save

First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories

PHASE1RECRUITING

This is a Single-center, Randomized, Double-blind, Placebo-controlled Phase I Study to Evaluate the Safety, Tolerability and PK Profiles of Single and Multiple Ascending Doses of Antimicrobial Peptide PL-18 Vaginal Suppositories.

Simpliy with AI

Study details:

Subjects who provide written informed consent to participate voluntarily in the clinical study will be screened. Eligible subjects will be sequentially enrolled into the above five sequential cohorts and randomized to receive PL-18 (cohort 1: n=8; cohort 2/3/4/5: n=6) or matching placebo (n=2). Subjects will be observed for 3 days after a single dose and receive PL-18 or placebo, once daily, for 6 consecutive days, if no grade ≥2 drug-related adverse events (AEs) occur.

During the study, PK sample collection, physical examination, vital signs, laboratory tests, electrocardiography (ECG) and tolerance evaluation will be performed based on the protocol schedule. To ensure the safety of the subjects, two sentinel subjects will be enrolled first in each cohort; one subject will be randomized to receive PL-18, and the other subject randomized to receive placebo. The safety data of the two sentinel subjects from initiation of single dosing to the last drug administration of multiple dosing on D11 will be reviewed by the investigator and sponsor before the subsequent subjects in that dose cohort are enrolled.

Subsequent subjects could be simultaneously enrolled, with one randomized to receive placebo and others randomized to receive PL-18.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Voluntarily signed written informed consent

Ability to comprehend the purpose of the study; ability to co-operate with the investigator and comply with all study requirements

Adult females aged between 18 and 55 years (inclusive)

Body weight between 50 and 100 kg (inclusive) and body mass index (BMI) within 18~32 kg/m2 (inclusive)

In good health as determined by screening tests. Good health is defined as having no clinically relevant abnormalities identified by a detailed medical history, full physical examination (including measurement of blood pressure and pulse rate), 12-lead ECG, and clinical laboratory tests: Vital signs (measured after resting for 5 minutes seated position) within normal range, or outside the normal range and not considered clinically significant by the Investigator; Standard 12-lead ECG parameters (recorded after resting for 5 minutes in supine position) in the following ranges; QTc (Fridericia algorithm recommended) ≤470 ms, and normal ECG tracing, or abnormal ECG tracing not considered clinically relevant by the Investigator; Laboratory parameters demonstrating no clinically significant abnormalities, as determined by the Investigator. A total bilirubin outside the normal range may be acceptable if total bilirubin does not exceed 1.5 × ULN conjugated bilirubin (with the exception of a participant with documented Gilbert syndrome)

Self-report regular menstrual cycle (21-35 days), and planned to avoid menstruation from the first administration until 7 days after the last administration

Negative human papilloma virus (HPV) test result (at screening or negative HPV test result performed in study site within 2 months prior to screening

History of sexual life, including vaginal intercourse

Be willing to use vaginal suppositories

Currently in a mutually monogamous sexual relationship or no sexual activity

Sexual abstinence from 72 hours prior to the first drug administration until 7 days after the last administration

Agreement to avoid the use of any other intravaginal products (i.e., contraceptive creams, gels, foams, sponges, lubricants, irrigation solutions, etc.) from screening until 7 days after the last administration

Subjects in a intercourse relationship must agree to use highly effective methods of contraception (as specified in Section 4.6.3) from informed consent obtained until 3 months after the last administration, and pregnancy test results must be negative at screening

Exclusion criteria

Significant deep epithelial disruption by colposcopy at screening

Anatomical anomalies of the genito-urinary tract and vaginal prolapse

Genitourinary infections at screening or within 21 days prior to screening, including but not limited to bacterial urinary tract infection, bacterial vaginosis, trichomoniasis and vulvovaginal candidiasis

Known, active sexually transmitted infection (STI) in partner, as per anamnesis

Two or more confirmed trichomoniasis, gonococcal, chlamydia trachomatis or syphilis spirochete infections within 180 days prior to screening

History of recurrent genital herpes or active herpes simplex virus (HSV) at screening

Hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), syphilis infection, or positive hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus antibody (HCVAb), HIV antibody (HIVAb), treponema pallidum antibody (TP-Ab) at screening

History of clinically severe relevant cardiovascular, hepatic, renal, pulmonary, gastrointestinal, endocrine, or neurological diseases that, in the investigator's opinion, may interfere with the aim of the study or affect the subject's safety

Uncontrolled or acute illness that may complicate the study evaluation in the investigator's opinion

History of hysterectomy

Pelvic surgery within 90 days prior to screening

Cervical cryotherapy or cervical laser treatment within 90 days prior to screening

Intrauterine device insertion or removal within 90 days prior to screening

Any antibiotic or antifungal therapy (intravaginal or systemic) within 30 days prior to screening

Immunosuppressive therapy within 60 days prior to screening

Ascertained or presumptive hypersensitivity (including allergies) to any ingredient of the investigational medicinal product (IMP); history of other significant anaphylaxis to drugs or allergic reactions in general

Pregnant or lactating women, or women within 60 days of the last pregnancy

Subjects who consume or are unable to abstain from products containing caffeine/xanthine within 24 hours before a visit or admission

History of drug or alcohol abuse within 1year prior to screening, or a positive result of drug abuse or alcohol breath test at screening or check-in

Previously dosed with an investigational drug within 3 months prior to Day 1 or still participating in another trial at the time of screening

Any vaccination from the 28 days prior to administration of the first dose until 28 days after the last dose

Those considered by the investigator as inappropriate to participate in the study

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : Yes

Gender eligible for study: Female

Things to know

Study dates

Study start: 2022-08-01

Primary completion: 2023-12-04

Study completion finish: 2024-03-01

Study type

TREATMENT

Phase

PHASE1

Trial ID

NCT05340790

Intervention or treatment

DRUG: Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories

DRUG: Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories

Conditions

• Colpomycosis
• Bacterial Vaginosis
• Mixede Vaginitis

Condition: Colpomycosis, Bacterial Vaginosis and more
DRUG: Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories and other drugs
Brisbane, Queensland, Australia
Sponsor: Protelight Pharmaceuticals Australia PTY LTD

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Q-Pharm Pty. Ltd

Research sites nearby

Select from list below to view details:

Q-Pharm Pty. Ltd
Brisbane, Queensland, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Antimicrobial Peptide PL-18 Vaginal Suppositories Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories	DRUG: Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
PLACEBO_COMPARATOR: Placebo dose Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories	DRUG: Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Characterize safety profile of Antimicrobial Peptide PL-18 Vaginal Suppositories about the incidence of treatment emergent adverse events	All AEs will be summarized by system organ class (SOC) and preferred term (PT). The numbers and percentages of subjects experiencing AEs will be calculated.	38 days
The numbers and percentages of subjects experiencing vital sign abnormalities with/without clinical significance.	Vital signs abnormalities will be summarized with descriptive statistics. Vital signs include body temperature, blood pressure, heart rate/pulse, respiration. Changes from the baseline of each test over time will be summarized.	17 days
The numbers and percentages of subjects experiencing physical examination abnormalities with/without clinical significance.	Physical examinations abnormalities will be summarized with descriptive statistics. Physical examination will include general condition, skin, head, eyes, ears, nose, throat, heart, lungs, chests, abdomen, extremities, nerves, back/spine, lymph, nodes. Changes from the baseline of each test over time will be summarized.	Day 4 , Day 11 , Day 17
Safety assessment about the changes of clinical laboratory tests.	Laboratory abnormalities will be summarized with descriptive statistics. Clinical laboratory tests include hematology, blood chemistry, level of immune factors, urinalysis.	Day2, Day 4 , Day5, Day 8, Day 11 , Day 17
Safety assessment about the changes of 12-lead ECG .	12-lead ECG abnormalities will be summarized with descriptive statistics.	Day1, Day 4 , Day 5, Day 7, Day 11 , Day 17

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Maximum plasma concentration (Cmax)	Concentrations of Antimicrobial Peptide PL-18 in Plasma samples at different time points are measured.Maximum plasma concentration (Cmax) is a PK parameter of the single-dose stage.Plasma concentrations at different time points will be listed and summarized by descriptive statistics.	Day1~Day4
Time to Maximum plasma concentration (Tmax)	Tmax is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.	Day1~Day4
Area under the concentration-time curve from the time zero to last measurable concentration (AUC0-t)	AUC0-t is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.	Day1~Day4
Area under concentration-time from time zero to infinity (AUC0-inf)	AUC0-t is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.	Day1~Day4
Terminal half-life (t1/2)	t1/2 is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.	Day1~Day4
Apparent clearance (CL/F)	CL/F is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.	Day1~Day4
Apparent volume of distribution (Vz/F)	Vz/F is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.	Day1~Day4
Mean residence time (MRT)	MRT is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.	Day1~Day4
Terminal elimination rate constant (λz)	λz is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.	Day1~Day4
Maximum observed concentration at steady state (Cmax,ss)	Concentrations of Antimicrobial Peptide PL-18 in Plasma samples at different time points are measured.Maximum observed concentration at steady state (Cmax,ss) is a PK parameter of the multi-dose stage.	Day5~Day 11
Minimum observed concentration at steady state (Cmin,ss)	Concentrations of Antimicrobial Peptide PL-18 in Plasma samples at different time points are measured. Minimum observed concentration at steady state (Cmin,ss) is a PK parameter of the multi-dose stage.	Day5~Day 11
The average concentration during a dosing interval at steady state (Cav,ss)	The average concentration during a dosing interval at steady state (Cav,ss) is a PK parameter of the multi-dose stage. Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.	Day5~Day 11
Area under the concentration-time curve from zero to the end of the dosing interval at steady state (AUCss)	AUCss is a PK parameter of the multi-dose stage. Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.	Day5~Day 11
Accumulation ratio (Rac)	Accumulation ratio (Rac) is a PK parameter of the multi-dose stage. Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.	Day5~Day 11
Characterize the effect of Antimicrobial peptide PL-18 Vaginal Suppositories on vaginal bacteria	Changes in vaginal bacteria after single and multiple doses of Antimicrobial Peptide PL-18 Vaginal Suppositories in healthy adult female subjects assessed. Changes in vaginal bacteria will be summarized with descriptive statistics.	17 days

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories